Jie Meng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jie Meng has a total of 157 co-authors. Here are the top co-authors by number of shared publications:
Mao Jiang
Department of Respiratory and Critical Care Medicine, Third Xiangya Hospital of Central South University, Changsha, Hunan, China
18 shared publicationsXiaoyun Cheng
Department of Pulmonary and Critical Care Medicine, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410000, China
15 shared publicationsLijian Tao
Department of Nephrology Xiangya Hospital Central South University Changsha China
14 shared publicationsLingzhi Long
Department of Pulmonary and Critical Care Medicine, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410000, China
14 shared publicationsGuoliang Jiang
Department of Pulmonary and Critical Care Medicine, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410000, China
13 shared publicationsXin Lv
Department of Nephrology Xiangya Hospital Central South University Changsha China
13 shared publications
Latest Publications
- Open Access
- 8 May 2026
- Published by Wiley in Advanced Science
- Vol. 13 (42) , e75449
Caveolin‐1 Stabilizes SERCA2 to Counteract Acute Kidney Injury via Suppression of Ca 2+ ‐Dependent Endoplasmic Reticulum Stress in Distal Tubules
Acute kidney injury (AKI) is a severe clinical condition with high morbidity and mortality. Caveolin‐1 (Cav‐1), a main structural protein of caveolae, orchestrates key cellular processes including endocytosis, lipid transport, and signal transduction by serving as a platform. However, its specific role in AKI remains unclear. Here, we report that Cav‐1 is upregulated in distal tubule epithelial cells (TECs) in both AKI patients and mouse models induced by ischemia/reperfusion injury (IRI) and lipopolysaccharide (LPS). Global and distal TEC‐specific Cav1 knockout exacerbates IRI and LPS‐induced AKI. RNA‐seq reveals that Cav‐1 deficiency exacerbates intracellular calcium ion (Ca 2+ ) homeostasis imbalance and endoplasmic reticulum (ER) stress in injured kidney tissues. Mechanistically, Cav‐1 interacts with sarcoplasmic/endoplasmic reticulum Ca 2+ ‐ATPase 2 (SERCA2), a key regulator of intracellular Ca 2+ homeostasis, through its scaffolding domain, promoting SERCA2 deubiquitination and stability in the ER, thereby maintaining intracellular Ca 2+ homeostasis and suppressing ER stress in distal TECs. Furthermore, supplementation with a cell‐permeable Cav‐1 scaffolding domain peptide (CSP) or activation of SERCA2 with a small‐molecule agonist CDN1163 alleviates IRI‐ and LPS‐induced AKI, while distal TEC‐specific SERCA2 knockdown abrogates CSP's therapeutic effect. Together, these findings reveal a novel Cav‐1‐mediated pathway and highlight its potential as a therapeutic target for AKI.
- 8 May 2026
- Published by Wiley in Advanced Science
- Vol. 13 (42) , e75449
Open AccessCaveolin‐1 Stabilizes SERCA2 to Counteract Acute Kidney Injury via Suppression of Ca 2+ ‐Dependent Endoplasmic Reticulum Stress in Distal Tubules
Acute kidney injury (AKI) is a severe clinical condition with high morbidity and mortality. Caveolin‐1 (Cav‐1), a main structural protein of caveolae, orchestrates key cellular processes including endocytosis, lipid transport, and signal transduction by serving as a platform. However, its specific role in AKI remains unclear. Here, we report that Cav‐1 is upregulated in distal tubule epithelial cells (TECs) in both AKI patients and mouse models induced by ischemia/reperfusion injury (IRI) and lipopolysaccharide (LPS). Global and distal TEC‐specific Cav1 knockout exacerbates IRI and LPS‐induced AKI. RNA‐seq reveals that Cav‐1 deficiency exacerbates intracellular calcium ion (Ca 2+ ) homeostasis imbalance and endoplasmic reticulum (ER) stress in injured kidney tissues. Mechanistically, Cav‐1 interacts with sarcoplasmic/endoplasmic reticulum Ca 2+ ‐ATPase 2 (SERCA2), a key regulator of intracellular Ca 2+ homeostasis, through its scaffolding domain, promoting SERCA2 deubiquitination and stability in the ER, thereby maintaining intracellular Ca 2+ homeostasis and suppressing ER stress in distal TECs. Furthermore, supplementation with a cell‐permeable Cav‐1 scaffolding domain peptide (CSP) or activation of SERCA2 with a small‐molecule agonist CDN1163 alleviates IRI‐ and LPS‐induced AKI, while distal TEC‐specific SERCA2 knockdown abrogates CSP's therapeutic effect. Together, these findings reveal a novel Cav‐1‐mediated pathway and highlight its potential as a therapeutic target for AKI.
- Open Access
- 25 February 2026
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 139 (7) , 1098-1100
Association of TyG-BMI and genetic risk with incident adult-onset asthma: Insights from the UK biobank
- 25 February 2026
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 139 (7) , 1098-1100
Open AccessAssociation of TyG-BMI and genetic risk with incident adult-onset asthma: Insights from the UK biobank
- Open Access
- 19 February 2026
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 13 (1) , e003687
Elevated serum peroxiredoxin 1 is a biomarker of multiorgan failure in ARDS
Background: Acute respiratory distress syndrome (ARDS) is a heterogeneous clinical syndrome with high morbidity and mortality. Despite advances in understanding its pathophysiology, definitive biomarkers for ARDS disease stratification and management remain lacking. This study evaluated the utility of circulating PRDX1 in predicting 28-day mortality in ARDS patients. Methods: A retrospective cohort study was conducted at Third Xiangya Hospital, enrolling 90 ARDS patients. Serum PRDX1 levels and clinical data were collected and compared with those from healthy volunteers and non-ARDS pneumonia patients to examine its alterations in ARDS patients; multivariate logistic regression and receiver operating characteristic (ROC) curve analyses were then employed to assess the prognostic value of circulating PRDX1 for 28-day mortality. An independent validation cohort of 20 ARDS patients was recruited from Xiangya Hospital intensive care units. Additionally, serum Prdx1 dynamics were assessed in LPS-induced acute lung injury (ALI) and sepsis-associated ALI murine models. Results: Serum PRDX1 levels were significantly elevated in a cohort of 90 ARDS patients, particularly among those with multiorgan injury. Multivariate analysis identified PRDX1 and age as independent risk factors for 28-day mortality. ROC curves revealed PRDX1’s prognostic utility (area under the curve, AUC=0.776, p<0.0001), which was comparable to the APACHE II score (AUC=0.778, p<0.0001). These findings were validated in the 20-patient cohort. Animal experiments confirmed that serum PRDX1 positively correlated with lung injury severity and exhibited earlier elevation and higher abundance in multiorgan injury contexts. Conclusions: Serum PRDX1 was significantly elevated in ARDS patients, particularly in those with multiorgan injury, and demonstrated potential as a prognostic biomarker, showing correlation with 28-day mortality. Its integration into the ARDS management framework holds significant potential for improving clinical outcomes.
- 19 February 2026
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 13 (1) , e003687
Open AccessElevated serum peroxiredoxin 1 is a biomarker of multiorgan failure in ARDS
Background: Acute respiratory distress syndrome (ARDS) is a heterogeneous clinical syndrome with high morbidity and mortality. Despite advances in understanding its pathophysiology, definitive biomarkers for ARDS disease stratification and management remain lacking. This study evaluated the utility of circulating PRDX1 in predicting 28-day mortality in ARDS patients. Methods: A retrospective cohort study was conducted at Third Xiangya Hospital, enrolling 90 ARDS patients. Serum PRDX1 levels and clinical data were collected and compared with those from healthy volunteers and non-ARDS pneumonia patients to examine its alterations in ARDS patients; multivariate logistic regression and receiver operating characteristic (ROC) curve analyses were then employed to assess the prognostic value of circulating PRDX1 for 28-day mortality. An independent validation cohort of 20 ARDS patients was recruited from Xiangya Hospital intensive care units. Additionally, serum Prdx1 dynamics were assessed in LPS-induced acute lung injury (ALI) and sepsis-associated ALI murine models. Results: Serum PRDX1 levels were significantly elevated in a cohort of 90 ARDS patients, particularly among those with multiorgan injury. Multivariate analysis identified PRDX1 and age as independent risk factors for 28-day mortality. ROC curves revealed PRDX1’s prognostic utility (area under the curve, AUC=0.776, p<0.0001), which was comparable to the APACHE II score (AUC=0.778, p<0.0001). These findings were validated in the 20-patient cohort. Animal experiments confirmed that serum PRDX1 positively correlated with lung injury severity and exhibited earlier elevation and higher abundance in multiorgan injury contexts. Conclusions: Serum PRDX1 was significantly elevated in ARDS patients, particularly in those with multiorgan injury, and demonstrated potential as a prognostic biomarker, showing correlation with 28-day mortality. Its integration into the ARDS management framework holds significant potential for improving clinical outcomes.
- Open Access
- 30 January 2026
- Published by Springer Nature in Respiratory Research
- Vol. 27 (1)
Peroxiredoxin 1 mediates bleomycin-induced acute lung injury in mice via macrophage NOD1/NF-κB axis
Bleomycin (BLM), a widely used antitumor drug, has been demonstrated to induce pulmonary toxicity in both chemotherapy patients and experimental animals, l
- 30 January 2026
- Published by Springer Nature in Respiratory Research
- Vol. 27 (1)
Open AccessPeroxiredoxin 1 mediates bleomycin-induced acute lung injury in mice via macrophage NOD1/NF-κB axis
Bleomycin (BLM), a widely used antitumor drug, has been demonstrated to induce pulmonary toxicity in both chemotherapy patients and experimental animals, l
- Open Access
- 19 January 2026
- Published by Elsevier in International Immunopharmacology
- Vol. 172, 116213
Succinate-mediated activation of the GPR91/MALT1/NF-κB/CCL2 pathway in macrophages contributes to pulmonary fibrosis
- 19 January 2026
- Published by Elsevier in International Immunopharmacology
- Vol. 172, 116213
Open AccessSuccinate-mediated activation of the GPR91/MALT1/NF-κB/CCL2 pathway in macrophages contributes to pulmonary fibrosis
- Open Access
- 10 December 2025
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 69 (12) , e0070225
Intrapulmonary penetration and pharmacokinetics of siderophore cephalosporin HRS-8427 injection in Chinese healthy subjects
HRS-8427, a novel siderophore cephalosporin antibiotic, is under development for treating Gram-negative infections. This study evaluated the intrapulmonary penetration and pharmacokinetic (PK) profile of HRS-8427 injection following single and multiple dose administrations in healthy Chinese subjects. A single-center, randomized, open-label Phase 1 trial enrolled 38 subjects, with 35 completing the study. In the single-dose group, subjects received a 1,500 mg intravenous infusion of HRS-8427 over 2 h. In the multiple-dose group, subjects were administered 2,000 mg of HRS-8427 intravenously every 8 h for four consecutive doses, each infused over 2 h. Bronchoalveolar lavage (BAL) was conducted to collect epithelial lining fluid (ELF) and alveolar macrophage (AM) specimens. PK analysis demonstrated a maximum plasma concentration ( C max ) of 176 µg/mL and an area under the time-concentration curve from time zero to time infinity (AUC 0–∞ ) of 942 h·μg/mL following the single 1,500 mg dose. After multiple 2,000 mg dosing, the C max increased to 262 µg/mlL with a corresponding AUC 0–∞ of 1,640 h·μg/mL. The ELF-to-plasma concentration ratio ( C ELF / C plasma ) exhibited a time-dependent increase, reaching 12.2% at 8 h post-final dose. Intracellular accumulation in AM remained minimal (<1%). Multiple-dose administration resulted in higher ELF exposure than single dosing. Safety assessments indicated an overall favorable tolerability profile, with most adverse events being mild in severity. Based on PK and microbiological data, a 2,000 mg regimen achieved concentrations exceeding the MIC₉₀ values of major Gram-negative pathogens, supporting further clinical development of HRS-8427 for respiratory and other Gram-negative bacterial infections. CLINICAL TRIALS: This study is registered with Chinese Clinical Trial Registry Platform as ChiCTR2300072350 .
- 10 December 2025
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 69 (12) , e0070225
Open AccessIntrapulmonary penetration and pharmacokinetics of siderophore cephalosporin HRS-8427 injection in Chinese healthy subjects
HRS-8427, a novel siderophore cephalosporin antibiotic, is under development for treating Gram-negative infections. This study evaluated the intrapulmonary penetration and pharmacokinetic (PK) profile of HRS-8427 injection following single and multiple dose administrations in healthy Chinese subjects. A single-center, randomized, open-label Phase 1 trial enrolled 38 subjects, with 35 completing the study. In the single-dose group, subjects received a 1,500 mg intravenous infusion of HRS-8427 over 2 h. In the multiple-dose group, subjects were administered 2,000 mg of HRS-8427 intravenously every 8 h for four consecutive doses, each infused over 2 h. Bronchoalveolar lavage (BAL) was conducted to collect epithelial lining fluid (ELF) and alveolar macrophage (AM) specimens. PK analysis demonstrated a maximum plasma concentration ( C max ) of 176 µg/mL and an area under the time-concentration curve from time zero to time infinity (AUC 0–∞ ) of 942 h·μg/mL following the single 1,500 mg dose. After multiple 2,000 mg dosing, the C max increased to 262 µg/mlL with a corresponding AUC 0–∞ of 1,640 h·μg/mL. The ELF-to-plasma concentration ratio ( C ELF / C plasma ) exhibited a time-dependent increase, reaching 12.2% at 8 h post-final dose. Intracellular accumulation in AM remained minimal (<1%). Multiple-dose administration resulted in higher ELF exposure than single dosing. Safety assessments indicated an overall favorable tolerability profile, with most adverse events being mild in severity. Based on PK and microbiological data, a 2,000 mg regimen achieved concentrations exceeding the MIC₉₀ values of major Gram-negative pathogens, supporting further clinical development of HRS-8427 for respiratory and other Gram-negative bacterial infections. CLINICAL TRIALS: This study is registered with Chinese Clinical Trial Registry Platform as ChiCTR2300072350 .
- Open Access
Aetiologic diagnosis of thoracic granulomatous diseases: a retrospective multicentre study in South-Central China
Objectives: To characterise the aetiological spectrum of thoracic granulomatous diseases and identify diagnostic features that facilitate differentiation among causes. Design: Retrospective multicentre observational study. Setting: Two tertiary hospitals in south-central China. Patient data were consecutively enrolled from 1 June 2020 to 30 June 2023. Participants: Of 2486 patients with pathologically confirmed thoracic granulomas initially identified, exclusions were applied for specimens outside the lung/pleura/mediastinum (579), incomplete demographic/imaging/pathology data (280) or lack of follow-up (231). A total of 1396 patients met all criteria (853 from hospital 1 and 543 from hospital 2) and were included in the final analysis. Primary and secondary outcome measures: We quantified the aetiologic distribution of thoracic granulomatous diseases and examined age-stratified/lesion-location differences in aetiologic patterns. We also evaluated associations between histopathological features and specific aetiologies and compared the diagnostic accuracy across sampling modalities. Results: Among the 1396 enrolled cases, a confident, probable and uncertain diagnosis was made in 1086 cases, 307 cases and 84 cases. Infectious granulomas predominated (89.4%; 1248/1396), with tuberculosis comprising 87.8% (1096/1248) of infectious cases. Among non-infectious granulomas, sarcoidosis was most common (65.8%; 50/76). Patients aged ≥60 years had a higher proportion of infectious granulomas than younger groups (≥60 years: 389/422; 40–60 years: 633/714; <40 years: 226/260; p=0.044). Fungal granulomas were more frequent in those aged 40–59 years (10.9% of infectious granulomas). Diagnostic accuracy was highest for surgical biopsy (93.5%, 288/305), followed by thoracoscopy (92.3%, 108/117) and transbronchial lung biopsy (74.7%, 510/683). Necrosis was present in 88.6% of granulomas; positive special stains were strongly associated with fungal infection. Conclusions: Most thoracic granulomas arise from mycobacterial or fungal infection, while sarcoidosis is the leading non-infectious cause. Thoracoscopy and surgical biopsy show superior diagnostic yields, and special staining aids differentiation of fungal aetiologies. Findings support a multidisciplinary approach to improve diagnostic accuracy.
Open AccessAetiologic diagnosis of thoracic granulomatous diseases: a retrospective multicentre study in South-Central China
Objectives: To characterise the aetiological spectrum of thoracic granulomatous diseases and identify diagnostic features that facilitate differentiation among causes. Design: Retrospective multicentre observational study. Setting: Two tertiary hospitals in south-central China. Patient data were consecutively enrolled from 1 June 2020 to 30 June 2023. Participants: Of 2486 patients with pathologically confirmed thoracic granulomas initially identified, exclusions were applied for specimens outside the lung/pleura/mediastinum (579), incomplete demographic/imaging/pathology data (280) or lack of follow-up (231). A total of 1396 patients met all criteria (853 from hospital 1 and 543 from hospital 2) and were included in the final analysis. Primary and secondary outcome measures: We quantified the aetiologic distribution of thoracic granulomatous diseases and examined age-stratified/lesion-location differences in aetiologic patterns. We also evaluated associations between histopathological features and specific aetiologies and compared the diagnostic accuracy across sampling modalities. Results: Among the 1396 enrolled cases, a confident, probable and uncertain diagnosis was made in 1086 cases, 307 cases and 84 cases. Infectious granulomas predominated (89.4%; 1248/1396), with tuberculosis comprising 87.8% (1096/1248) of infectious cases. Among non-infectious granulomas, sarcoidosis was most common (65.8%; 50/76). Patients aged ≥60 years had a higher proportion of infectious granulomas than younger groups (≥60 years: 389/422; 40–60 years: 633/714; <40 years: 226/260; p=0.044). Fungal granulomas were more frequent in those aged 40–59 years (10.9% of infectious granulomas). Diagnostic accuracy was highest for surgical biopsy (93.5%, 288/305), followed by thoracoscopy (92.3%, 108/117) and transbronchial lung biopsy (74.7%, 510/683). Necrosis was present in 88.6% of granulomas; positive special stains were strongly associated with fungal infection. Conclusions: Most thoracic granulomas arise from mycobacterial or fungal infection, while sarcoidosis is the leading non-infectious cause. Thoracoscopy and surgical biopsy show superior diagnostic yields, and special staining aids differentiation of fungal aetiologies. Findings support a multidisciplinary approach to improve diagnostic accuracy.
- Open Access
- 10 October 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-11
Prognostic risk factors and a survival prediction model for immune checkpoint inhibitor related myocarditis in patients with lung cancer: a multicenter study
Immune checkpoint inhibitor (ICI)-related myocarditis is a rare but fatal immune-related adverse event in lung cancer patients, with limited multivariate prognostic analysis. This study aimed to identify risk factors for severity, major adverse cardiac events (MACE) and survival time, and develop a survival prediction model. Data from 70 lung cancer patients with ICI-related myocarditis (training set) and 40 patients (validation set) were analyzed, with ≥ 1.5 years of follow-up. Cox regression was employed to determine factors associated with survival time, and Logistic regression models identified risk factors for severe myocarditis and MACE. Several factors were independently associated with all-cause death: protective factors included combined radiotherapy (HR 0.12, 95%CI: 0.01–0.98, p = 0.047) and longer ICI treatment duration (≥ 132 days, HR 0.93, 95%CI: 0.91–0.98, p = 0.013); risk factors included low-dose glucocorticoid use in patients with severe myocarditis (HR 3.92, 95%CI: 1.16–13.2, p = 0.028). A nomogram model constructed based on these three variables yielded area under the time-ROC curves of 0.832, 0.835, and 0.924 for 0.5-, 1-, and 1.5-year survival in the training set, and 0.821, 0.806, and 0.789 in the validation set, respectively. It also demonstrated good discriminative ability and clinical utility for predicting survival in lung cancer patients with ICI-related myocarditis, as this study established a validated nomogram model that may aid survival prediction in this population. Additionally, we analyzed the risk factors for severe ICI related myocarditis and 90-day MACE. We found that the use of angiogenesis inhibitors was an independent risk factor for severe myocarditis (OR 18.72, 95% CI: 2.52–428.27, p = 0.02); a history of coronary artery disease (OR 10.54, 95% CI: 1.62–210.10, p = 0.037) was an independent risk factor for 90-day MACE; and left ventricular ejection fraction (OR 0.94, 95% CI: 0.88–0.99, p = 0.026) was an independent protective factor against 90-day MACE.
- 10 October 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-11
Open AccessPrognostic risk factors and a survival prediction model for immune checkpoint inhibitor related myocarditis in patients with lung cancer: a multicenter study
Immune checkpoint inhibitor (ICI)-related myocarditis is a rare but fatal immune-related adverse event in lung cancer patients, with limited multivariate prognostic analysis. This study aimed to identify risk factors for severity, major adverse cardiac events (MACE) and survival time, and develop a survival prediction model. Data from 70 lung cancer patients with ICI-related myocarditis (training set) and 40 patients (validation set) were analyzed, with ≥ 1.5 years of follow-up. Cox regression was employed to determine factors associated with survival time, and Logistic regression models identified risk factors for severe myocarditis and MACE. Several factors were independently associated with all-cause death: protective factors included combined radiotherapy (HR 0.12, 95%CI: 0.01–0.98, p = 0.047) and longer ICI treatment duration (≥ 132 days, HR 0.93, 95%CI: 0.91–0.98, p = 0.013); risk factors included low-dose glucocorticoid use in patients with severe myocarditis (HR 3.92, 95%CI: 1.16–13.2, p = 0.028). A nomogram model constructed based on these three variables yielded area under the time-ROC curves of 0.832, 0.835, and 0.924 for 0.5-, 1-, and 1.5-year survival in the training set, and 0.821, 0.806, and 0.789 in the validation set, respectively. It also demonstrated good discriminative ability and clinical utility for predicting survival in lung cancer patients with ICI-related myocarditis, as this study established a validated nomogram model that may aid survival prediction in this population. Additionally, we analyzed the risk factors for severe ICI related myocarditis and 90-day MACE. We found that the use of angiogenesis inhibitors was an independent risk factor for severe myocarditis (OR 18.72, 95% CI: 2.52–428.27, p = 0.02); a history of coronary artery disease (OR 10.54, 95% CI: 1.62–210.10, p = 0.037) was an independent risk factor for 90-day MACE; and left ventricular ejection fraction (OR 0.94, 95% CI: 0.88–0.99, p = 0.026) was an independent protective factor against 90-day MACE.
- Open Access
- 30 May 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 160, 114971
Mefunidone treats pulmonary fibrosis by targeting SDH to regulate fibro-promoting macrophages
- 30 May 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 160, 114971
Open AccessMefunidone treats pulmonary fibrosis by targeting SDH to regulate fibro-promoting macrophages
- 6 September 2024
- Published by Elsevier in Toxicology Letters
- Vol. 401, 55-70
Exosomal miR-552-3p isolated from BALF of patients with silicosis induces fibroblast activation
- 6 September 2024
- Published by Elsevier in Toxicology Letters
- Vol. 401, 55-70
Exosomal miR-552-3p isolated from BALF of patients with silicosis induces fibroblast activation